226 related articles for article (PubMed ID: 25980552)
21. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
Kornstein SG; Dunner DL; Meyers AL; Whitmyer VG; Mallinckrodt CH; Wohlreich MM; Detke MJ; Hollandbeck MS; Greist JH
J Clin Psychiatry; 2008 Sep; 69(9):1383-92. PubMed ID: 19193339
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
[TBL] [Abstract][Full Text] [Related]
24. Early symptom change prediction of remission in depression treatment.
Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
[TBL] [Abstract][Full Text] [Related]
25. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
Mowla A; Dastgheib SA; Razeghian Jahromi L
Clin Drug Investig; 2016 Jul; 36(7):539-43. PubMed ID: 27071759
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
Fornaro M; Martino M; Mattei C; Prestia D; Vinciguerra V; De Berardis D; De Pasquale C; Iasevoli F; Mungo S; Fornaro P
Eur Neuropsychopharmacol; 2014 Aug; 24(8):1269-78. PubMed ID: 24842649
[TBL] [Abstract][Full Text] [Related]
27. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
28. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
30. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Katona C; Hansen T; Olsen CK
Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
[TBL] [Abstract][Full Text] [Related]
34. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
35. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
36. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.
Gueorguieva R; Mallinckrodt C; Krystal JH
Arch Gen Psychiatry; 2011 Dec; 68(12):1227-37. PubMed ID: 22147842
[TBL] [Abstract][Full Text] [Related]
37. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
39. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
40. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
Kornstein SG; Fava M; Jiang Q; Tourian KA
Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]